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Abstract 
The perspective of neuronflammation as an epiphenomenon following neuron damage is being 
replaced by the awareness of glia and their importance in neural functions and disorders. Systemic 
inflammation generates signals that communicate with the brain and leads to changes in metabolism 
and behavior, with microglia assuming a pro-inflammatory phenotype. Identification of potential 
peripheral-to-central cellular links is thus a critical step in designing effective therapeutics. Mast 
cells may fulfill such a role. These resident immune cells are found close to and within peripheral 
nerves and in brain parenchyma/meninges, where they exercise a key role in orchestrating the 
inflammatory process from initiation through chronic activation. Mast cells and glia engage in 
cross-talk that contributes to accelerate disease progression; such interactions become exaggerated 
with aging and increased cell sensitivity to stress. Emerging evidence for oligodendrocytes, 
independent of myelin and support of axonal integrity, points to their having strong immune 
functions, innate immune receptor expression, and production/response to chemokines and 
cytokines that modulate immune responses in the central nervous system while engaging in cross-
talk with microglia and astrocytes. In this review we summarize the findings related to our 
understanding of the biology and cellular signalling mechanisms of neuroinflammation, with 
emphasis on mast cell-glia interactions. 
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Introduction 
Organisms are endowed by nature with various self-defense mechanisms to maintain homeostasis. 
As an example, the innate immune system is equipped to distinguish between friend and foe or self 
and non-self. One important component of such natural mechanisms is inflammation (Nathan and 
Ding 2010).  Most of us would probably associate inflammation with pain, yet this complex 
biological response is a fundamental part of the body's response to injury and infection designed to 
eliminate the initial cause of cell injury and initiate tissue repair. In most cases the inflammatory 
event is innocuous and brief, as the swelling and itching of a mosquito bite. Inflammation is 
associated also with serious, chronic disorders such as inflammatory bowel disease and rheumatoid 
arthritis (Castellheim and others 2009). Manifestation of inflammation in the nervous system 
('neuroinflammation') can be especially perilous. Although not a primary cause of disease, 
neuroinflammation contributes importantly to the pathogenesis of chronic pain and neuropathic pain 
(Ellis and Bennett 2014; Martini and Willison 2016; Myers and others 2006), chronic 
neurodegenerative diseases (Amor and others 2014; Freeman and Ting 2015; Iadecola and Anrather 
2011; McGeer and McGeer 2013; Ransohoff 2016), neuropsychiatric illness (Castanon and others 
2015; Najjar and others 2013; Theoharides and others 2015; Wohleb and others 2016), autism 
spectrum disorder (Noriega and Savelkoul, 2014; Theoharides and others 2016), and probably even 
temporal lobe epilepsy (Marchi and others 2014). Intriguingly, there appears to be close link 
between psychosocial stressors and neuroinflammation (Calcia and others 2016; Rivat and others 
2010). A common theme in the above pathologies is the persistent nature of inflammation. As 
Nathan and Ding (2010) pointed out: "The problem with inflammation is not how often it starts, but 
how often it fails to subside". Without doubt, non-resolving inflammation is one of the principal 
contributors to the medical burden in today’s society. 
Our understanding of the immune system’s role in neuroinflammation came to light with the 
revelation that extensive bi-directional lines of communication exist between the former and the 
central nervous system (CNS). Inflammatory cytokines and chemokines occupy a key niche in this 
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highway, regulating host responses to infection, inflammation, stress and trauma (Le Thuc and 
others 2015). Mast cells and microglia (the principal neuroimmune sentinels of the brain), two 
innate immune system cell types, together with astrocytes, represent key protagonists linking 
peripheral immune signalling to the brain in an inflammatory setting. These cell populations 
constitute important sources of inflammatory mediators and may have cardinal roles in conditions 
ranging from neuropathic pain (Miller 2005; Old and others 2015; Pekny and others 2016; Peng and 
others 2015; Sakamoto and others 2016; Thacker and others 2007) to neurodegenerative diseases 
(Amor and Woodruffe 2014; Appel and others 2011; Cunningham, 2013; Harcha and others 2015; 
Medeiros and LaFerla 2013; Ransohoff 2016; Silver and Curley 2013) and neuropsychiatric 
disorders (Prinz and Priller 2014; Theoharides and others 2015; Wohleb and others 2016). Such 
interactions take on added significance with aging, in which the process of ‘immunosenescence’ 
leads to increased sensitivity of microglia and mast cells to environmental stressors and may well be 
a factor in low-grade non-resolving inflammation in the elderly (Skaper 2015). 
The realization that inflammation is an integral feature of numerous neurological conditions - 
for which in many cases there is no adequate therapy - leaves an enormous unmet medical need. 
However, progress in understanding the nature of inflammation’s origin and contribution to disease 
pathobiology is growing rapidly, as investigators explore nervous system-immune interactions. It 
bears mentioning that the above considerations have not addressed another key glial cell type, 
which is abundant in the CNS, namely, the oligodendrocyte. These myelin-producing cells also 
support axonal functions and long-term integrity, have strong immune functions, express a wide 
variety of innate immune receptors, and produce and respond to chemokines and cytokines that 
modulate immune responses in the CNS and engage in cross-talk with other glia cell types. The 
intent of this review will be to describe recent contributions in our understanding of the biology and 
cellular signaling mechanisms of neuroinflammation, with emphasis on a mast cell-glia (microglia, 
astrocyte, oligodendrocyte) interactions. 
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Mast Cells 
A number of cell types participate in neuroinflammation, including glia and immune system-
derived cells, both tissue-resident and blood-borne. Neuroinflammation-oriented reviews generally 
focus on the roles of microglia and other immune cell types such as T cells, along with astrocytes 
(Grace and others 2014; Hanisch and Kettenmann 2007; Le Thuc and others 2015; Old and others 
2015). While glial cell activation represents an important contribution to neuropathology, these cells 
are responsive also to inflammatory signals originating from other cells of immune origin, such as 
mast cells. These granulated resident immune cells, first described by Paul Ehrlich in the late 19th 
century (Ehrlich 1878) are close relatives to basophil granulocytes in blood, both expressing CD34 
and containing cytoplasmic granules loaded with histamine and heparin, the former released upon 
engagement of IgE. Tissue mast cells have a unique haematopoietic lineage development: unlike 
other myeloid-derived cells, immature lineage progenitors, once entering the circulation undergo 
transendothelial recruitment into peripheral tissues which regulate the appearance of secretory 
granules with a particular protease phenotype (Box 1) (Prussin and Metcalfe 2003). Apart from 
their participation in innate host defense reactions, mast cells display a widespread perivascular 
tissue distribution, and are found predominantly at the interface between the host and the external 
environment – as such they are strategically placed to act not only as first responders in harmful 
situations but also as environmental ‘sensors’ to communicate with other cellular elements involved 
in physiological and/or immune responses (da Dilva and others 2014). Mast cells occur in 
peripheral tissues innervated by small calibre sensory nerve fibres (Fig. 1) and within the 
endoneurial compartment of peripheral nerves, as well as in meninges and cerebral blood vessels. 
They are capable of phagocytosis and antigen presentation, and can modulate acquired immune 
responses  (via the high-affinity IgE receptor, FcεRI) (Kalesnikoff and Galli 2008). Mast cells have 
long been known to participate in inflammatory processes, and are present and recruited to all 
inflammatory sites. Indeed, mast cells play an important role in orchestrating the whole 
inflammatory process from initiation events to chronic activation (Box 1). 
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Activated mast cells secrete a plethora of vasoactive, pro-nociceptive and pro-inflammatory 
mediators, from biogenic amines, cytokines, enzymes, lipid metabolites and ATP, to neuropeptides, 
growth factors (i.e. tumor necrosis factor alpha (TNF-) interleukin (IL)-1,2,3,4,6, and 13, nerve 
growth factor (NGF) and vascular endothelial growth factor (VEGF)) and nitric oxide (Fig. 2) 
(Kalesnikoff and Galli 2008; Silver and Curley 2013). Mast cell heterogeneity is a function of their 
tissue location and species, which is reflected in the repertoire of mediators elaborated. Within the 
context of their immune regulatory role they release chemoattractants that recruit eosinophils 
(Wardlaw and others 1986) and monocytes (Perry and others 1993). In addition to serving as 
effector cells, mast cells are capable of inducing T cell activation, recruitment, proliferation, and 
cytokine secretion in an antigen-dependent manner (Bulfone-Paus and Bahri 2015). Mast cell – T 
helper cell cooperation is expressed in terms of the immunological synapse (or immune synapse / 
supramolecular activation cluster (Monks and others 1998)), a structure which forms during 
recognition of peptide fragments (antigens) of pathogens bound to major histocompatibility 
complex II molecules on antigen-presenting cells (e.g. mast cells)  by the T cell receptor (Grakoui 
and others 1999). We usually think of synapses as long-lasting structures formed between two 
neurons, or between neurons and a non-neuronal target cell such as muscle cells. Although immune 
synapses are more short-lived than neural synapses, they are nevertheless structured and essential 
for cell activation. Lymphocyte function-associated antigen 1 (LFA-1) is expressed by T cells, B 
cells, macrophages and neutrophils. It functions as an adhesion molecule by binding to intercellular 
adhesion molecule-1 (ICAM-1) on antigen-presenting cells (e.g. mast cells; Fig. 2) (Varma and 
others 2006). Further, the interaction between CD28 on T cells and its ligands CD86 and CD80 on 
mast cells is crucial for an optimal activation of antigen-specific T cells. T cell stimulation through 
CD28 in addition to the T-cell receptor can provide a potent signal for the production of various 
interleukins (Nakajima and others 1997). A complex relationship between actin dynamics and T cell 
activation appears to exist, with T cell polarization driven by actin cytoskeleton remodelling (Kwon 
and others 2008); the cytoskeleton of the antigen-presenting cell may also play an active role in T 
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cell activation (Comrie and Burkhardt 2016). In addition, mast cell secretion of  TNF- and direct 
cell-cell interactions between mast cell OX40L and T cell OX40 contribute to the ability of IgE- 
and antigen-stimulated mast cells to enhance T cell activation (Nakae and others 2006) and polarize 
the secretory machinery of the latter towards the mast cell (Gaudenzio and others 2009). Mast cells 
are involved in the development of various T cell-associated immune responses, including 
experimental autoimmune encephalomyelitis (EAE) (Gregory and others 2006), as will be discussed 
later in this review. 
   
Blood-brain barrier 
Healthy brain vessels possess a functional blood-brain barrier (BBB) which supports cells of the 
surrounding brain parenchyma, while protecting it from immune cells and harmful substances in the 
blood. Mast cells are found within the dura and meninges, and on the brain side of the BBB where 
they contact astrocytic end-feet (Silver and Curley 2013). Mast cells are able to traverse a healthy 
BBB (Silverman and others 2000), as well as the blood-spinal cord barrier (and BBB) in 
pathological conditions.  Ischemia-triggered mast cell degranulation appears to play a role in 
initiating the early phase of ischemic damage (Lindsberg and others 2010). Increased mast cell 
degranulation has been reported after stroke in the immature brain (Biran and others 2008) and 
transient global ischemia in the adult rat (Hu and others 2004). Cerebral mast cells, through their 
release of proteases regulate acute microvascular gelatinase (matrix metalloproteinases-2 and -9) 
activation, thereby effecting BBB disruption following transient cerebral ischemia (Mattila et al., 
2011). Another factor, not often considered, is the potential role of VEGF. Elevated VEGF levels 
contribute to early stroke pathology, including BBB breakdown, vascular leakage and edema. BBB 
disruption by VEGF increases extravasation of glutamate and albumin, in turn activating astrocytes 
and altering K+ homeostasis in brain parenchyma leading to hyperexcitation of neurons (Lapilover 
and others 2012) and entry of inflammatory cells. Indeed, VEGF administration shortly after stroke 
increases vascular leakage and brain infarction (Zhang and others 2000). Activated microglia 
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secrete prostaglandin E2, which induces VEGF expression in mast cells (Li and others 2015). 
Prolonged VEGF elevation increases angiogenic sprouting and causes breakdown of the BBB 
(Lange and others 2016). Indeed, pharmacological or genetic manipulation of mast cells in rat 
models reduces BBB permeability, brain edema and neutrophil recruitment after ischemia (Jin and 
others 2007; Mattila and others 2011), and diminishes brain edema and hematoma volume and 
improves outcome after experimental intracerebral hemorrhage (Strbian and others 2007).  Using a 
mouse model of focal cerebral ischemia, McKittrick and others (2015) describe that mast cells act 
on the basal membrane, thus promoting BBB damage, brain edema, prolonged extravasation, 
neutrophil infiltration and hemorrhage. Moreover, it has been postulated that in EAE activation of 
meningeal mast cells elicits production of TNF- and early neutrophil recruitment, thereby 
promoting breakdown of the local BBB and cerebrospinal fluid-blood barrier allowing initial 
immune cell (e.g. T cells) access to the CNS (Christy and others 2013; Sayad and others 2010). 
These findings suggest that meningeal inflammation anticipates CNS immune cell infiltration and 
point to mast cells as among the earliest participants in these disease-initiating events (Christy and 
others 2013). 
Elderly patients often experience postoperative cognitive dysfunction following surgery and 
hospitalization (Terrando and others 2011). It has been suggested that extra-CNS surgical trauma, 
by provoking neuroinflammation, may be a critical contributor to surgery-induced cognitive 
dysfunction (Riedel and others 2014). Inflammatory mediators released by surgical stress may 
damage synapses and neurons, and ultimately lead to postoperative cognitive dysfunction 
(Eckenhoff and Laudansky 2013). Cerebral mast cells have been suggested to contribute to 
postoperative cognitive dysfunction by promoting BBB breakdown (Zhang and others 2016). It is 
intriguing also that acute stress (immobilization) may increase BBB permeability through activation 
of brain mast cells (Esposito and others 2001). 
 
Blood-nerve barrier 
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Mast cells are present within the endoneurium, and their stimulation is capable of markedly altering 
blood-nerve barrier permeability, endoneurial fluid composition and nerve conduction (Harvey and 
others 1994). In an experimental model of diabetes produced by hyperglycemia, the authors 
observed a significant rise in permeability to [14C]-labeled mannitol and water content, as well as 
significant increases in numbers of degranulating perivascular mast cells (Kalichman and others 
1995). 
 
Mast Cells and Glia in Inflammation-Associated Chronic Neuropathologies 
Glial cells are activated in response to a number of different pathological states within the CNS, 
including chronic neurodegenerative disorders. Given the vast literature surrounding this facet of 
neuroinflammation, we will focus instead on evidence supporting their involvement along with 
mast cells in representative disease states. The reader is referred to several excellent recent reviews 
(Lull and Block 2010; Medeiros and LaFerla 2013; Smith and others 2011).  
 
Alzheimer disease 
An expanding body of evidence posits that Alzheimer disease (AD) pathogenesis is not restricted to 
the neuronal compartment, but encompasses interactions with immunological mechanisms in the 
brain. Indeed, microglia and astrocytes are key players in the pro-inflammatory environment of AD 
brain. Changes in microglia and astrocytes have been observed in the post-mortem brains of 
individuals with AD and in mouse transgenic models of AD over-expressing a mutant amyloid 
precursor protein and presenilin 1 bearing deposits of insoluble amyloid β-peptide (Aβ) (plaques) 
(Heneka and others 2015; Parvathenani and others 2003). Microglia surrounding Aβ plaques in the 
frontal cortex of AD brain reportedly contain IL-1β-positive microglia (Heneka and others 2015). 
Amyloid precursor protein reportedly also regulates microglial phenotype in a mouse model of AD 
(Manocha and others 2016). Triggering receptor expressed on myeloid cells 2 (TREM-2) is part of 
the immunoglobulin and lectin-like superfamily and functions as part of the innate immune system. 
TREM-2 is highly expressed by microglia (Hickman and others 2013) and mediates phagocytic 
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clearage of neuronal cell debris (Takahashi and others 2007). Mutations in this gene may be risk 
factors for AD (Guerreiro and others 2013). An endogenous ligand from TREM-2 has yet to be 
identified; however, TREM binding activity (a possible indication of TREM-2 ligand expression) 
has been observed on reactive astrocytes surrounding Aβ plaques and on damaged neurons and 
oligodendrocytes (Hsieh and others 2013; Heneka and others 2015). 
 Post-mortem studies of AD patients have evidenced mast cells close to amyloid plaque lesions 
in different brain regions (Maslinska and others 2007), although their involvement in disease onset 
and/or progression remains to be elucidated. Harcha and others (2015) have recently shed light on 
this question by showing that acute treatment of cultured mast cells with Aβ25-35 peptide activates 
Panx1 hemichannels, which mediate Ca2+ influx degranulation. Brain mast cells exhibited increased 
Panx1 and Cx43 hemichannel activity after acute Aβ25-35 treatment, which was accompanied by 
enhanced histamine release. In addition, mast cell numbers increased in cortex and hippocampus 
before onset of amyloid plaque formation and showed increased Panx1 and Cx43 hemichannel 
activity in a mouse model of AD. These authors suggest that mast cells are among the first brain 
cells to sense Aβ peptides and thus may play a critical role in the onset and progression of AD 
(Harcha and others 2015).  
Traumatic brain injury (TBI) acts as an important epigenetic risk factor for AD (Sivanandam 
and Thakur 2012). Subjecting AD transgenic mice to TBI worsens behavioural deficits and 
aggravates Aβ deposition (Tajiri and others 2013), possibly due to immune cell dysregulation. Fluid 
percussion TBI resulted in cortical mast cell increase and changes in regulation of central histamine 
receptors (Lozada and others 2005).  Mild TBI in the form of concussive head injury evoked 
persistent dural mast cell degranulation for at least 30 days, while blast trauma gave rise to a 
delayed mast cell degranulation response commencing at seven days that also persisted for at least 
30 days (Levy and others 2015). Moreover, TBI leads also to microglial cell activation, which may 
be both rapid (Koshinaga and others 2000) and persistent following the injury event (Ertürk and 
others 2016; Ramlackhansingh and others 2011). Pro-inflammatory cytokines released by mast cells 
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and microglia can up-regulate expression of β-secretase (Sastre and other 2003), resulting in 
increased production of amyloidogenic Aβ species (Corrigan and others 2011). Mast cells are also 
early responders in the hypoxic-ischemic neonatal rat, their numbers increasing in ipsilateral 
hemisphere within the first several hours and prior to neuronal cell apoptosis and 
astrocyte/microglia activation. 
 
Multiple sclerosis 
MS is an inflammatory autoimmune disease characterized by the destruction of CNS myelin which 
insulates axons (Compston and Coles 2008), thereby allowing the rapid conduction of electrical 
impulses and delivery of the action potential to the target cell. MS is the most common cause of 
chronic neurological impairment in young people (Kamm and others 2014). Myelin destruction is 
initiated by the myelin-reactive T cells, and is further amplified by the inflammatory response of 
myeloid cells, including the brain-resident microglia and infiltrating inflammatory macrophages 
(Sospedra and Martin 2016). Microglia-mediated proteolysis of TREM-2 produces soluble TREM-2 
(sTREM-2). Cerebrospinal fluid levels of sTREM-2 were reported increased in patients with 
relapsing-remitting MS, secondary progressive MS, and primary progressive MS, returning to 
control level with immunomodulatory drug (natalizumab) treatment (Öhrfelt and others 2016). Mast 
cells are also considered as playing an important role in the pathogenesis of MS (Conti and 
Kempuraj 2016; Kritas and others 2014; Theoharides and others 2008), where they mediate 
inflammation and demyelinization by presenting myelin antigens to T cells and/or disrupting the 
BBB to permit entry of inflammatory cells and cytokines. Degranulating mast cells are seen in the 
brain of rats with EAE (Brenner and others 1994). Mast cells can be activated by myelin (Medic 
and others 2008), cause demyelination (Theoharides and others 1991) and induce oligodendrocyte 
death (Medic and others 2010). In mouse EAE models, however, some investigators argue for a 
lack of clear evidence whether mast cell effects on EAE development depend on mouse strain, 
immunization protocol, or type and severity of the disease (Nelissen and others 2013). 
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 Granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine produced by T 
helper cells, plays a key role in orchestrating neuroinflammation in EAE.  Meningeal mast cells 
appear to be an important contributor to myelin-specific T cell  accumulation and GM-CSF 
expression, as T cells neither accumulate in meninges nor produce GM-CSF in the absence of mast 
cells (Russi and others 2016a,b). These authors also showed, by means of mast cell-T cell co-
culture experiments and selective mast cell reconstitution of the meninges of mast cell-deficient 
mice that meningeal mast cells are an early source of caspase-1-(inflammasome)-dependent IL-1β 
which, in turn, promotes GM-CSF expression by T cells and their encephalitogenicity. Further, 
acute MS patients appear to display mast cell-T cell co-localization in the meninges and CNS 
(Russi and others 2016b). Russi and colleagues (2016a) propose that mast cell-T cell crosstalk in 
the meninges is critical for EAE disease development and, possibly, also in human demyelinating 
disease (Russi and colleagues 2016b). 
IL-17A is associated with many inflammatory and autoimmune diseases and may be involved 
in MS. Local production of IL-17A is not limited to cells involved in adaptive immune responses 
such as Th17 cells and cytotoxic T cells (Kolbinger and others 2016), but also innate immune cells 
such as mast cells (Kan and others 2016). IL-17A synergizes with other pro-inflammatory cytokines 
(e.g. those released by microglia and mast cells themselves), inducing the release of additional 
cytokines and chemokines that recruit new inflammatory cells. IL-17A adversely affects the 
functions of microglia, astrocytes, oligodendrocytes, neurons, neural precursor cells and endothelial 
cells (Kolbinger and others 2016). 
IL-33, the newest member of the IL-1 cytokine family is implicated in a number of 
inflammatory and autoimmune diseases (Liew and others 2010). The IL-33 receptor, consisting of 
ST2 and IL-1 receptor accessory protein, is expressed particularly by T helper 2 cells and mast cells 
(Liew and others 2010). IL-33 is generally released as a danger signal ("alarmin") from damaged 
cells, and may also be processed and released from activated mast cells with subsequent autocrine 
and paracrine actions. IL-33 not only augments the stimulatory effects of IgE and substance P (SP) 
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on mast cells but can also trigger the release of cytokines from mast cells per se (Theoharides and 
others 2015). IL-33 inflammatory activity includes up-regulation of IL-6, IL-8, and IL-13. IL-33 is 
up-regulated in both the periphery and the CNS of MS patients (Christophi and others 2012), and 
administration of a blocking anti-IL-33 antibody in EAE mice during the induction phase 
significantly inhibited disease onset and severity (Li and others 2012). In human brain, IL-33 is 
expressed by various CNS resident cells including neurons, astrocytes, oligodendrocytes and 
microglia, while its receptor ST2 is mainly expressed by neurons. Expression levels and patterns of 
IL-33 and ST2 in acute and chronic MS brain lesion samples were enhanced compared with normal 
brain tissues (Allan and others 2016). These authors also demonstrated that IL-33 inhibits 
myelination in rat myelinating spinal cord co-cultures. Approximately 30-40% of patients with MS 
suffer from central neuropathic pain (Osterberg and others 2005). Conceivably, this could be linked 
to spinal cord oligodendrocyte-derived IL-33, and its reciprocal relationship with IL-33-induced 
production of TNF- and IL-1β in spinal cord (Zarpelon and others 2016).        
 
Neuropathic pain 
Acute pain is self-limiting and serves a protective biological function by acting as a warning of on-
going tissue damage. It is a symptom of a disease process experienced in or around the injured or 
diseased tissue. Chronic pain, on the other hand, serves no protective biological function. Rather 
than being the symptom of a disease process, chronic pain is itself a disease process. Persistent pain 
represents a substantial and growing unmet medical need, affecting nearly half of people seeking 
medical care in the United States alone. Among all types of chronic pain, neuropathic pain stands 
out: as defined by the International Association for the Study of Pain, it results from damage or 
disease affecting the somatosensory system (Jensen and others 2011). Neuropathic pain may be 
either peripheral or central, depending on lesion location caused by diseases such as diabetes 
mellitus, herpes zoster, human immunodeficiency virus infection, medical interventions 
(chemotherapy, surgery), and injury, while the latter are most often caused by stroke, spinal cord 
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injury or multiple sclerosis (Kerstman and others 2013). In the case of peripheral neuropathic pain 
(painful neuropathy) chronic pain should be considered a brain disease in which alterations in 
neural networks affect multiple aspects of brain function, structure and chemistry (Borsook 2012). 
Neuropathic pain is associated with significant medical care costs and decreased worker 
productivity (Jay and Barkin 2014; Smith and Torrance 2012), with an estimated 3-4.5% of the 
global population affected by neuropathic pain - with the rate of incidence increasing as the global 
population ages (Smith and Torrance 2012). Indeed, a more recent systematic review of 
epidemiological studies estimates a population prevalence of pain with neuropathic characteristics 
to lie between 6.9% and 10% (van Hecke and others 2014). 
Immune cells, in particular mast cells and microglia are co-protagonists of the somatosensory 
system, acting as the primary interlocutors for pain neurons, both in the periphery and at the spinal 
and supraspinal levels. Persistent alterations in mast cells and microglia lead to changes that 
promote persistent neuroinflammation which, in turn, impacts the functionality of neurons. Mast 
cell degranulation not only triggers the release of molecules (e.g. IL-6) which activate or sensitize 
nociceptors and directly contribute to neuropathic pain (Xanthos and others 2011) but also activates 
trigemino-cervical and lumbosacral pain pathways to elicit widespread tactile pain hypersensitivity 
(Levy and others 2012), the latter action possibly mediated by a sensitizing effect of histamine on 
nociceptors. By constituting the first line of activation at the site of damage, peripheral nerve-
resident mast cells promote the recruitment of neutrophils and macrophages (Zuo and others 2003). 
Further, NGF, which can sensitize nociceptors by engaging their high-affinity TrkA receptors (and 
indirectly via other cell types) (Kelleher and others 2016) is rapidly released by mast cells (Leon 
and others 1994). Interestingly, mast cells respond to NGF in a paracrine/autocrine manner (Leon 
and others 1994). Working together, these events facilitate T-cell recruitment to reinforce and 
maintain inflammatory reactions. Mast cells may enhance recruitment of other key immune cell 
types which, in turn, release pro-nociceptive mediators. A role for mast cells in chronic pain states 
is further supported by recent studies showing that: glucocorticoid therapy reduces pain and TNF-α-
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positive mast cell numbers in rats with chronic constrictive nerve injury (Hayashi and others 2011); 
mast cells are important mediators of chronic visceral pain (Done and others 2012). These concepts 
are schematically illustrated in more detail in Fig. 3. 
Glia are important mediators of pain processes at the spinal level (Old and others 2015; Grace 
and others 2014). Microglia interact with spinal neurons at the site of injury, for example, by 
synthesizing and releasing IL-1β that modulates neuronal cell activity (Watkins and others 2003), 
and can be activated through a number of cell surface molecules as well as respond to pro-
inflammatory signals released from peripheral cells of immune origin, such as mast cells. Microglia 
express several subtypes of ionotropic P2X and metabotropic P2Y purinergic receptors that play a 
role in pain signalling in the spinal cord under pathological conditions (e.g. peripheral nerve injury) 
(Biber and others 2011; Kobayashi and others 2008; Skaper and others 2010). In such settings, 
dorsal horn microglia become activated with up-regulation of purinergic receptors which participate 
in neuropathic pain (Burnstock 2016; Tsuda 2016). Inhibiting the function or expression of these 
microglial receptors suppresses the aberrant excitability of dorsal horn neurons and neuropathic 
pain (Tsuda 2016), underlining spinal microglia as an important player in mechanisms for 
neuropathic pain and potential target for treating chronic pain states. In addition to the accepted 
roles for the P2X and P2Y receptors activated by ATP and ADP, respectively, recent evidence 
suggests a role also for the adenosine A2A receptor in microglial cytoskeletal rearrangements (Orr 
and others 2009; Luongo and others 2014) and the adenosine A1 receptor in moderating ATP-
induced over-excitability of nociceptive neurons after microglia application to the spinal cord 
(Luongo and others 2014). 
Cross-talk between mast cells and microglia, directly via cellular mediators and indirectly 
through somatosensory neurons, may contribute to amplification of peripheral pain signals at the 
spinal level (Bulanova and Paus 2010). Activated microglia contribute to pain states by releasing 
pro-inflammatory cytokines, chemokines, and proteases. Peng and others (2016) have suggested 
that microglia and monocytes may act synergistically to promote the transition from acute to 
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chronic pain after nerve injury. In addition, systemic inflammation can generate signals that 
communicate with the brain, leading to alterations in metabolism and behavior, including 
expression of a pro-inflammatory phenotype by microglia (Cunningham 2013). Astrocytes, the 
most abundant CNS glial cell type involved in neuroinflammation, also play a major role in pain 
facilitation and are a key contributor to neuropathic pain (Ji and others 2014; Milligan and Watkins 
2009). The above findings encourage the notion that controlling mast cell-glia reactivity can 
provide an attractive therapeutic avenue for treating neuropathic pain (Gao and Ji 2010; Popiolek-
Barczyk and Mika 2016; Skaper and Facci 2012). In this context it is interesting to point out that 
acute intracerebroventricular administration of N-palmitoylethanolamine, a congener of the 
endocannabinoid anandamide with analgesic and anti-inflammatory activities linked to mast cell / 
microglia modulation (Alhouayek and Muccioli 2014), reduced carrageenan-induced paw 
edema/hyperalgesia and prevented nuclear factor-B nuclear translocation in the spinal cord 
(D’Agostino and others 2007), supporting central involvement of these immune cells in peripheral 
inflammation.    
To study the mechanisms of persistent pain, animal models of inflammatory hyperalgesia that 
mimic human clinical pain conditions have been developed based on the injection of inflammatory 
agents into the rat or mouse hind paw (Millan and others 1988). Neurogenic inflammation arises 
from the local release of inflammatory mediators from afferent neurons such as SP, calcitonin gene-
related peptide, neurokinin A, and endothelin-3 (Geppetti and others 2008). Further, NGF 
(presumably mast cell-derived) can trigger nociception via transient receptor potential vanilloid 1 
(TRPV1) and oxidative mechanisms (Eskander and others 2015). Once released, these 
neuropeptides provoke the egress of histamine from adjacent mast cells which, in turn, evokes the 
release of SP and calcitonin gene-related peptide - thus establishing a bidirectional link between 
histamine and neuropeptides in neurogenic inflammation (Rosa 2013). SP strongly induces VEGF 
in mast cells, and IL-33 contributes to the stimulation and release of VEGF in human mast cells in a 
dose-dependent manner and acts synergistically in combination with SP (Theoharides and others 
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2010) (Fig. 4). Within this context, incubation of rat peritoneal mast cells with NGF, together with 
specific antigen or SP to induce degranulation, leads to a significant increase in secretion of 
preloaded [3H]serotonin (Table 1); neither BDNF nor neurotrophin-3 was active. 
The above considerations concerning chronic pain have not addressed another important glial 
cell type, which is abundant in the CNS, namely, oligodendrocytes. The latter cells are responsible 
for producing the myelin that ensheaths axons and forms the nodes of Ranvier that permit saltatory 
nerve conduction. More recently, additional roles for oligodendrocytes have come to light, 
including provision of trophic factors and metabolic support for neurons (Bankston and others 
2013), as well as support of axonal functions and long-term integrity in a myelin-independent 
fashion (Nave 2010). For example, oligodendrocyte ablation in mice results in axonal pathology in 
the spinal dorsal horn and spinothalamic tract concurrent with the induction and maintenance of an 
exaggerated nociceptive sensitivity prior to frank demyelination independent of innate or adaptive 
immune responses (Gritsch and others 2014). Moreover, oligodendrocytes also have strong immune 
functions, express a wide variety of innate immune receptors, and produce and respond to 
chemokines and cytokines that modulate immune responses in the CNS (Peferoen and others 2014; 
Zeis and others 2016) and engage in cross-talk with microglia (Peferoen and others 2014). 
Inflammation triggers the production of N,N-dimethylsphingosine (DMS) in the dorsal horn, and its 
intrathecal administration is sufficient to induce neuropathic pain-like behavior in rats (Patti and 
others 2012). Interestingly, cultured human oligodendrocytes produce DMS, with DMS levels 
increasing when these cells are challenged with agents that damage white matter (Chen and others 
2014), suggesting that damage to oligodendrocytes in vivo leads to increased DMS production 
which in turn drives inflammatory astrocyte responses involved in sensory neuron sensitization. In 
addition, a new study demonstrates that that spinal cord oligodendrocyte-derived IL-33 mediates 
neuropathic pain (Zarpelon and others 2016). An intriguing link between oligodendrocytes and 
NGF comes from a recent report by von Büdingen and others (2015), in which the authors 
demonstrate the direct binding of NGF to myelin oligodendrocyte glycoprotein, a minor component 
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of myelin and the only protein exclusively restricted to the outermost lamellae of compact CNS 
myelin (and which shares structural features with TrkA). Based on their findings, these authors 
posit that myelin oligodendrocyte glycoprotein may serve as a protective mechanism to deplete 
excess NGF and thereby prevent aberrant sprouting and neuropathic pain after peripheral nerve 
injury. Whether this mechanism links CNS demyelination with neuropathic pain as, for example, in 
MS (Solaro and others 2013) remains to be determined. Collectively, the above observations point 
to a heretofore unexpected role of oligodendrocytes in mediating neuropathic pain. The potential for 
crosstalk between the various glial cell types discussed will be explored further in the following 
section. 
  
Mast Cells and Glia: a Complex Communication Network 
Recruitment and activation of different immune cell populations in a defined temporal pattern 
requires reciprocal communication amongst these cells. Consider, for example, brain-derived 
neurotrophic factor (BDNF), which plays a key role in eliciting pain hypersensitivity. Peripheral 
nerve injury up-regulates the purinergic P2X4 receptor in spinal microglia to mediate BDNF release 
and neuropathic pain (Ulmann and others 2008), and depends on mast cell tryptase cleavage of 
proteinase-activated receptor 2 (PAR2) to activate PAR2-bearing microglia (Yuan and others 2010). 
Microglia-released IL-6 and TNF-α, up-regulating PAR2 expression on nearby mast cells (Zhang 
and others 2010) could, as the authors suggest, result in a BDNF-driven feedback loop between 
these cells. 
Extracellular ATP is a ubiquitous danger signal released from infected or damaged cells, acting 
via purinoceptors on target cells, and is an important signaling pathway in the development of 
neuropathic pain (Burnstock 2016). ATP is a potent stimulus for microglia. Expression of different 
P2 receptor subtypes can vary as a function of the species and source from which mast calls are 
derived (Bulanova and Bulfone-Paus 2010). ATP from one mast cell can diffuse several hundred 
micrometers trigger a rise in Ca2+ in neighboring cells (Osipchuk and Cahalan 1992). Microglia 
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whose Toll-like receptors have been activated by pathogen-associated molecular patterns respond to 
ATP with the release of IL-33 which can subsequently bind to its cognate mast cell receptor and 
induce the secretion of inflammatory molecules to modulate glial cell activity. 
There is evidence to suggest that elements of the complement system also participate in this 
crosstalk. The chemoattractant C5a receptor is up-regulated on reactive astrocytes and microglia 
and C5a is released in neuroinflammation (Griffin and others 2007). The latter acts as a strong 
chemoattractant signal for mast cells whose C5a receptor is up-regulated upon activation of these 
cells. 
Cluster of differentiation 40 (CD40) is a co-stimulatory protein found on antigen-presenting cells 
(including mast cells; Fig. 2) and is required for their activation. The binding of CD154 (CD40L) 
on T helper cells to CD40 activates antigen presenting cells and induces a variety of downstream 
effects. Studies by Kim and others (2011) point to the existence of cross-talk between of astrocytes 
and mast cells through CD40-CD40L interaction which induces cytokine and chemokine production 
via Rho-family GTPases/Ca2+-dependent protein kinase C isoforms, mitogen-activated protein 
kinases, nuclear factor-κB and signal transducer and activator of transcription 1. These cytokines 
subsequently re-activate astrocytes, and enhance the production of a variety of cytokines. 
Toll-like receptors (TLRs) represent a major class of pathogen-associated molecular patterns, 
molecules associated with groups of pathogens recognized by innate immune system cells (e.g. 
microglia and mast cells). Activation of mast cell TLR2/TLR4 triggers cytokine release which 
recruits immune cells to the sites of injury; microglia recruitment depends on signaling pathways 
involving TLR2/TLR4 (Aguirre and others 2013; Pietrzak and others 2011). Mast cell activation 
up-regulates also chemokine expression (e.g. CCL5/RANTES), which can induce a pro-
inflammatory response in microglia, as well. Further, microglia-derived IL-6 and CCL5 may, in 
turn, affect mast cell expression of TLR2/TLR4. Table 2 summarizes the above-discussed points. 
Conceivably, glia – glia interactions could comprise an additional element whereby glia and 
mast cells work in concert to promote neuroinflammation. For example, Wang and others (2014) 
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have demonstrated microglia – astrocyte interaction at the level of translocator protein, a marker of 
gliosis in neurodegeneration. Microglia and astrocytes are also capable of exercising a reciprocal 
interaction through their release of pro-inflammatory cytokines/chemokines (Le Thuc and others 
2015). Moreover, a crosstalk between oligodendrocytes and microglia has been proposed, involving 
exosomes - small vesicles containing proteins, lipids and regulatory RNAs (Peferoen and others 
2014) (Box 2).  
 
Immunosenescence 
Non-resolving inflammation takes on added significance in the context of aging, a phenomenon 
associated with elevated levels of circulating cytokines and pro-inflammatory markers, and age-
related changes in the immune system (so-called 'immunosenescence') (Mate and others 2014; 
Michaud and others 2013). The changes that mast cells and microglia undergo as the organism ages 
represent an important element of immunosenescence. Mast cells have been observed to display 
various alterations in the aging animal, such as: reprogramming of degranulation (expressed as 
heightened sensitivity to prostaglandin E2) (Nguyen and others 2005); increased cell numbers in the 
dermis (role in tissue damage and aging changes in skin?) (Gunin and others 2011); decline in cell 
development due to senescent stromal cell impairment (Tsuboi and others 2011). Dysregulation of 
microglia is likely to play a prominent role in aging, as well. Aging models are characterized by an 
increased inflammatory state of microglia, 'primed' to be activated and resistant to regulation 
(Eggen and other 2013; Norden and Godbout 2013; Rawji and others 2016). Priming renders 
microglia susceptible to a secondary inflammatory stimulus, which can then trigger an exaggerated 
inflammatory response (Perry and Holmes 2014) (Fig. 5). The age-related decline of myelin 
proteins was found to be highly correlated with activation of astrocytes and microglia in the rat 
CNS (Xie and others 2013). Age-related myelin degradation (and possibly also oligodendrocyte 
turnover) (Young and others 2013) burdens the clearance function of microglia during aging, 
thereby leading to lysosomal storage and possibly contributing to microglial senescence and 
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immune dysfunction in aging (Safaiyan and others 2016). It has also been suggested that the 
alarmin high mobility group box 1 (HMGB1), which can be released under chronic pathological 
conditions and initiate inflammatory cascades, mediates neuroinflammatory priming in the aged 
brain (Fonken and others 2016). Moreover, priming of spinal microglia following activation by 
diverse forms of peripheral trauma/inflammation can lead to enhanced pain intensity / duration 
(Hains and others 2010).When the aged brain’s immune system is challenged, microglial activation 
is amplified and prolonged. Left unchecked, this primed state of microglia may ultimately manifest 
itself in deleterious behavioral and cognitive consequences. Interestingly, dystrophic (senescent) 
rather than activated microglial cells are associated with tau pathology in human brain and have 
been suggested to precede neurodegeneration in AD (Streit and others 2009). The appearance of 
dystrophic microglia has been noted also in mouse brain with aging Cristino and others 2015; 
Punzo and others 2016).  
The ability of microglia and mast cells to communicate with each other may very well 
exacerbate the effects of aging on these cells’ pro-inflammatory traits. Obesity (Kim and Do 2015), 
along with diabetes (Donath 2014) and cancer (Diakos and others 2014) are now recognized as 
chronic low-grade inflammatory states. Not surprisingly, incidence of the latter conditions generally 
increases with age, placing the elderly at greater risk for a state of low-grade, non-resolving 
inflammation. This concept has an underlying experimental basis, whereby Morris and others 
(2015) demonstrated that an endotoxin-induced, persistent state of low-grade inflammation is 
associated with innate immune programming. On a side note, there is mounting evidence that acute 
and chronic inflammatory pain states, including neuropathic pain (which is associated with low-
grade chronic inflammation), markedly alter BBB permeability (Dos Santos and others 2014), 
perhaps as a consequence of changes in tight junction proteins (Brooks and others 2005). Loss of 
BBB integrity has been linked, as well, to cognitive dysfunction in aging (Chan-Ling and others 
2007; Pelisch and others 2013; Rapp and others 2008).   
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Conclusions and Perspectives 
Inflammation is a protective reaction initiated following injury or infection, and is intended to 
promote tissue repair and healing. When dysregulated, however, inflammation is transformed into a 
key pathological process in diverse disease states. Neuroinflammatory disorders are conditions 
where immune responses damage components of the nervous system, and can be especially 
devastating. Microglia represent well-described sensors for disturbed brain tissue homeostasis and 
accumulate locally in response to neuronal cell injury or entry of foreign material into the brain. 
Yet, we still have much to learn about resident brain cell types capable of mounting immediate host 
responses in the brain and meninges, such as mast cells. These innate immune effector cells have 
the capacity to evoke both a rapid and longer-term delayed responses. As discussed in this review, a 
highly complex interplay exists between a number of non-neuronal cells in the nervous system, 
including microglia, astrocytes, mast cells and oligodendrocytes (Fig. 6). Inclusion of the last cell 
type is a relatively recent addition to the equation, yet perhaps not all that surprising given the fact 
that they express a wide range of innate immune receptors, and produce and respond to chemokines 
and cytokines that modulate immune responses across the CNS. 
These cellular behaviors, with their interconnected lines of communication can present a 
challenge when designing strategies to deal with the resolution of inflammation-associated 
neurological disorders (Fullerton and Gilroy, 2016). This issue is especially relevant when 
confronting chronic and neuropathic pain where, for the majority of patients, treatment options are 
woefully insufficient. For instance, opioids, the treatment of choice for acute severe pain, are 
contraindicated for chronic usage due to many side effects and their abuse potential, and newer 
anticonvulsants prescribed for pain are only effective for about one-third of patients. These two 
classes of drugs act primarily on neuronal circuits of the brain and spinal cord and treat the 
symptoms but not the underlying pathophysiology. Mast cell-stabilizing agents like cromolyn 
suppress development of hyperalgesia but do not affect microglia. Microglial inhibitors like 
minocycline, which are often used in pain models rely on their anti-inflammatory properties but 
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may be limited due to non-selectivity in targeting one cell population and the risk of acute or 
cumulative toxicity. An agent which is capable of modulating activation across glia as well as mast 
cells, while at the same time devoid of immunosuppressive activity, might prove efficacious in the 
resolution of inflammation and even restoration of tissue homeostasis.  
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Box 1 
 
The basics of mast cell biology  
 
 
Mast cells were first described by Paul Ehrlich in 1878 based on their unique staining 
characteristics and large cytoplasmic granules – a feature unique to these cells. They share 
certain features with another blood-borne immune cell, the basophil, although mast cells 
appear to be generated by different precursor cells in the bone marrow expressing CD34. The 
hematopoietic lineage development of tissue mast cells is unique compared to other myeloid-
derived cells because it is early lineage progenitors, histochemically undetectable, that leave 
the bone marrow to enter the circulation. Immature lineage mast cells undergo 
transendothelial recruitment into peripheral tissues where they differentiate; appearance of 
secretory granules with a particular protease phenotype is regulated by the peripheral tissue. 
We now recognise two mast cell types, namely, those from connective tissue and a distinct 
set of mucosal mast cells – the latter’s activities being dependent on T-cells. Mast cells found 
throughout all vascularised tissues, often close to blood vessels. Their prominence near 
boundaries between the body’s external environment and the internal milieu (e.g. skin, lung 
mucosa and digestive tract), as well as in mouth, conjunctiva and nasal passages leaves them 
well-placed to function as sentinel cells in host defense. Mast cells are found also within the 
nervous system, including meninges, the brain parenchyma and peripheral nerves. 
Mast cells play a key role in the inflammatory process, and their activation leads to rapid 
release of granules into the interstitium. Degranulation can be caused by a number of factors, 
including direct injury (e.g. physical or chemical), cross-linking of IgE receptors or by 
activated complement proteins. Mast cells have the capacity to release a wide array of 
bioactive agents, including cytokines, nociceptive peptides, chemoattractants and growth 
factors.These molecules can be transferred to adjacent cells of the immune system and 
neurons via transgranulation and their pseudopodia. In addition, they express a number of 
"pattern recognition receptors" which may allow them to recognize broad classes of 
pathogens. 
Mast cells play important roles in diseases both outside and within the nervous 
system, including allergic reactions and anaphylactic shock, chronic and neuropathic 
pain, degenerative and traumatic neurological pathologies, mood disorders and autism. 
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Box 2 
 
Exosomes 
 
 
Exosomes are cell-derived vesicles widely distributed in virtually all eukaryotic fluids, 
including medium from cultured cells. They were initially observed in the maturing 
mammalian reticulocyte, and shown to participate in selective removal of many plasma 
membrane proteins. In most mammalian cells the plasma membrane is being continually 
recycled and portions internalized as endosomes, after which membrane parts of some 
endosomes are internalized as smaller vesicles called multivesicular bodies. Exosomes may 
follow two routes: release from the cell when multivesicular bodies fuse with the plasma 
membrane; direct release from the plasma membrane. Exosomes have specialized functions 
and appear to play key roles in coagulation, intercellular signalling, and scavenging.  These 
vesicles contain a variety of molecular constituents of their cell of origin, including proteins 
and RNA. The protein composition of exosomes can vary with cell and tissue of origin, but 
the majority of exosomes contain an evolutionarily-conserved common set of proteins. 
Exosomes are thought to provide a means of intercellular communication and of transmission 
of macromolecules between cells via membrane vesicle trafficking, thereby influencing the 
immune system. In recent years, exosomes have been considered as having roles in the spread 
of proteins, lipids, mRNA, microRNA and DNA and as contributing factors in the 
development of several diseases. Given these properties of exosomes, there is now much 
interest in clinical applications of exosomes, with potential applications in prognosis, therapy, 
and as biomarkers. 
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Figure legends 
 
Fig. 1. Safranin staining highlights cytoplasmic granules (red) in a tissue mast cell, located in close 
proximity to a small blood vessel and myelinated nerve fiber (note node of Ranvier). Degranulating 
mast cells have a wide ‘footprint’, their granules being able to travel up to 50 µm. This strategic 
location can influence the function of vascular structures as well as axons. (Image courtesy of Lucia 
Petrelli, Department of Neuroscience, University of Padua)  
 
Fig. 2. The mast cell: a multifaceted immune cell. Schematic representation of mast cell activators 
and molecules. Mast cell activation triggers the rapid release of preformed effectors (tumor necrosis 
factor (TNF), interleukin-4 (IL-4) and granulocyte macrophage-colony stimulating factor (GM-
CSF), among others) as well as de novo synthesis of cytokines (TNF), chemokines, and growth 
factors (e.g. nerve growth factor). Cell adhesion molecule 1 (CADM1) on mast cells promotes 
interaction with peripheral nociceptive neuron terminals via heterophilic binding to nectin-3 
(Hagiyama and others 2013; Ito and Oonuma 2006). Intercellular contacts between T helper cells 
and antigen-presenting cells like mast cells initiate T-cell signaling, whereby T-cell surface 
receptors recognize antigens bound to major histocompatibility complex molecules on the antigen-
presenting cell (Suurmond and others 2013). This process (which also engages adhesion receptors) 
creates a specialized junction between the two cell types – the so-called immunological synapse 
(Choudhuri and others 2014), which mediates delivery of effector molecules (via microvesicles) 
and intercellular signals across this cleft – in effect polarizing the secretory machinery of the T cell 
towards the mast cell. Cluster of differentiation 86 (CD86) is a protein expressed on antigen-
presenting cells providing co-stimulatory signals necessary for T cell activation and survival. CD28 
Engagement between CD28 on T cells and CD86 on mast cells is crucial for an optimal activation 
of antigen-specific T cells. TCR, T cell receptor.  
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Fig. 3. In physiological conditions, pain information begins at the nerve endings, which form a 
functional pain unit with the nearby tissue capillaries. Peripheral mast cells are a key element in this 
functional unit, given their proximity to sensory nerve endings and vasculature (Forsythe and 
Bienenstock 2012). Following injury or inflammatory stimuli, mast cell mediators (histamine, 
bradykinin, prostaglandins, some microRNAs) stimulate nociceptive afferents (Kajihara and other 
2010; Park and others 2014). Neuropeptides (e.g. substance P) may also provoke mast cell 
degranulation, leading to a bidirectional positive feedback-loop (Matsuda and others 1989) to up-
regulate local inflammation and increase pain. Mast cell recruitment of other immune cells, which 
release pro-nociceptive mediators, can affect not only injured zones but also adjacent territories, 
creating a secondary, widespread hyperalgesia (Zuo and others 2003). At the spinal level, mediators 
released from dural mast cells may reach the superficial laminae to modulate synaptic transmission 
and nociception (Michaloudi and others 2008). CNS mast cells are believed to have a role in central 
integration of pain, being especially concentrated in the thalamus -  an essential nociceptive relay 
whose release of mediators such as histamine or serotonin might interact with third-order neurons 
targeting the cortex (Héron and Dubayle 2013; Silver and Curley 2013). Peripheral and brain mast 
cells cooperate with microglia and other immune cells to orchestrate onset of central sensitization. 
In fact, in the absence of a tight physiological control, mast cell-nerve terminal activity results in 
nociceptor sensitization, reduced pain threshold at the site of inflammation and, ultimately, 
dysfunctional pain signaling and hyperalgesia (Demir and others 2013; Zuo and others 2003). 
Persistent increased responsiveness of nociceptors can also sensitize spinal cord neurons, leading to 
central sensitization (Dirckx and others 2013).  
 
Fig. 4. Peripheral sensitization and neurogenic inflammation. The interaction between nociceptive 
terminals and tissue mast cells conditions the peripheral threshold to pain. A lack of proper mast 
cell control, e.g. in response chemical, dysmetabolic or infective noxae leads to the abnormal 
release of growth factors like vascular endothelial growth factor (VEGF) and nerve growth factor 
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(NGF) which can cause neoinnervation and angiogenesis, as well as vasoactive amines (histamine, 
HIST) to provoke vasodilitation, edema and inflammatory cell infiltration.  In neurogenic 
inflammation mediators like substance P (SP) are directly released from sensory nerves (slow 
velocity C-fibers) to produce vasodilatation, edema, and other manifestations of inflammation. 
Additionally, NGF can trigger nociception via transient receptor potential vanilloid 1 (TRPV1). SP 
induces the release of histamine from mast cells which, in turn, evokes the release of SP and 
calcitonin gene-related peptide from nerve terminals - thus establishing a bidirectional link between 
histamine and neuropeptides in neurogenic inflammation. SP strongly induces VEGF in mast cells, 
and IL-33 contributes to the stimulation and release of VEGF in human mast cells in a dose-
dependent manner and acts synergistically in combination with SP.   
 
Fig. 5. Schematic illustration of the effects of aging on microglial cell responsiveness to stress or 
injury. Age-related changes in the immune system (immunosenescence) are characterized by an 
increased inflammatory state of microglia, 'primed' to be activated and resistant to regulation. 
Priming renders microglia susceptible to a secondary inflammatory stimulus, which can then trigger 
an exaggerated inflammatory response (represented by the extended, red curve). 
 
Fig. 6. Neuroinflammation may result from CNS neurons being impinged upon by a microglia-
astrocyte-mast cell network, as a result of inadequate regulation of these non-neuronal cells due to 
excessive and/or persistent endogenous and/or endogenous stimuli, and/or an inadequate cellular 
inhibitory capacity. Two-way communication between microglia, mast cells and astrocytes may act 
to reinforce deleterious signals acting on the neuron. The oligodendrocyte adds another level of 
complexity to this interacting network of non-neuronal cells, being both a target and source of 
signals directed to the latter cell populations (Kiray and others 2016). Oligodendrocytes have strong 
immune functions, express a wide variety of innate immune receptors, and produce and respond to 
chemokines and cytokines that modulate immune responses in the CNS.      
